Isomorphic Labs Raises $2.1 Billion to Scale Its AI-Powered Drug Design Engine

Isomorphic Labs, the Google DeepMind spin-off on a mission to “solve all disease” with artificial intelligence, has secured $2.1 billion in Series B funding — one of the largest financing rounds ever seen in the AI drug discovery space. The round was led by Thrive Capital, with significant participation from Alphabet and GV, and joined by new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

The newly raised capital will be used to accelerate the development and deployment of the company’s proprietary AI Drug Design Engine (IsoDDE), expand its pipeline of therapeutic programmes toward the clinic, and scale talent across its global sites — including its research hub in London (UK) and Lausanne, (Canton of Vaud, Switzerland).

A Swiss Anchor in the Heart of European Biotech

Lausanne is no secondary outpost for Isomorphic Labs. Opened in May 2023 at the EPFL Innovation Park and since relocated to a permanent office in the city center, the Swiss hub plays a central role in the company’s technology development. Led by Chief Technology Officer Sergei Yakneen — who chose Lausanne for its exceptional scientific talent pool and entrepreneurial ecosystem — the team currently counts around 30 specialists in AI research and data engineering, with further hiring underway. The proximity to EPFL, one of Europe’s top engineering universities, makes Lausanne a natural home for the kind of deep, interdisciplinary work Isomorphic pursues.

A Platform Built to Redefine Drug Discovery

At the core of Isomorphic’s approach is IsoDDE, a unified AI engine capable of operating across multiple therapeutic areas and drug modalities. Building on the Nobel Prize-winning AlphaFold model — which revolutionized protein structure prediction — the company has developed a suite of proprietary AI models designed to design better drug candidates faster and at lower cost. Recent publications have highlighted IsoDDE’s predictive accuracy and its ability to bridge the gap between structural biology and real-world drug design.

The company already holds strategic partnerships with Novartis, Eli Lilly, and Johnson & Johnson, and is advancing both partnered and wholly-owned programmes in oncology and immunology.

➡️ Source: Press Release | 📸 ©Isomorphic Labs